Press Releases – BeiGene LTD

Mar 04, 2019

BeiGene to Present at Upcoming Investor Conferences read more...

Feb 27, 2019

BeiGene Reports Fourth Quarter and Full Year 2018 Financial Results read more...

Feb 22, 2019

BeiGene to Present at the 8th SVB Leerink Global Healthcare Conference read more...

Feb 19, 2019

BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma read more...

Feb 13, 2019

BeiGene to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019 and Host Investor Event in Hong Kong read more...

Feb 07, 2019

BeiGene to Present at the Guggenheim Healthcare Talks Idea Forum – Oncology Day read more...

Jan 14, 2019

BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib in Mantle Cell Lymphoma read more...

Jan 03, 2019

BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) read more...

Dec 17, 2018

BeiGene Initiates Two Global Phase 3 Front-Line Clinical Trials of Tislelizumab, in Patients with Gastric Cancer and in Patients with Esophageal Cancer read more...

Dec 15, 2018

BeiGene Announces Updated Phase 1A/1B Data on Tislelizumab Presented at the European Society for Medical Oncology Immuno-Oncology Congress read more...

Dec 10, 2018

BeiGene to Present Clinical Data on Anti-PD-1 Antibody Tislelizumab at the European Society for Medical Oncology Immuno-Oncology Congress read more...

Dec 05, 2018

BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) read more...

Dec 03, 2018

BeiGene Presents Clinical Results of Tislelizumab in Relapsed/Refractory Classical Hodgkin’s Lymphoma at the 60th American Society of Hematology Annual Meeting read more...

Dec 01, 2018

BeiGene Announces Clinical Results of Zanubrutinib in Mantle Cell Lymphoma From Two Presentations at the 60th American Society of Hematology Annual Meeting read more...

Nov 28, 2018

Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks’ Azymetric™ and EFECT™ Platforms Globally read more...

Nov 20, 2018

BeiGene to Present at the 30th Annual Piper Jaffray Healthcare Conference read more...

Nov 16, 2018

BeiGene Announces Preliminary Clinical Data on PARP Inhibitor Pamiparib Presented at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology read more...

Nov 15, 2018

Priority Review Granted to BeiGene’s New Drug Applications for Zanubrutinib and Tislelizumab in China read more...

Nov 13, 2018

BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) read more...

Nov 07, 2018

BeiGene Initiates Global Head-to-Head Phase 3 Clinical Trial of Zanubrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma read more...